Skip to main content

2011 to 2023 Saw Increase in New GLP-1 Receptor Agonist Prescriptions

Medically reviewed by Carmen Pope, BPharm. Last updated on July 23, 2024.

By Elana Gotkine HealthDay Reporter

MONDAY, July 22, 2024 -- From 2011 to 2023, there was an increase in new glucagon like peptide 1 receptor agonist (GLP-1RA) prescriptions, according to a research letter published online July 23 in the Annals of Internal Medicine.

Yee Hui Yeo, M.D., from Cedars-Sinai Medical Center in Los Angeles, and colleagues examined nationwide trends in GLP-1RA prescription patterns, stratified by indications, using data from a federated health research network with deidentified records of about 45 million persons.

The researchers found that the 1 million new GLP-1RA users were disproportionately female, non-Hispanic White, and those with a body mass index (BMI) of ≥30 kg/m2. Age- and sex-standardized incidence of new GLP-1RA use increased during 2011 to 2023, especially after 2020. When categorized by indication, the proportion of new GLP-1RA users with type 2 diabetes decreased. However, a twofold increase was seen in the proportion of users without type 2 diabetes, but with a BMI of ≥30 kg/m2, or those with a BMI of 27 to 30 kg/m2 and an obesity-related comorbid condition during the same period. From 2019 to 2023, the proportion of users without U.S. Food and Drug Administration-approved indications increased from 0.21 to 0.37 percent. In 2019, semaglutide and liraglutide accounted for 31.4 and 35.3 percent of all new GLP-1RA prescriptions, while these proportions were 88.1 and 10.3 percent, respectively, in 2023.

"We revealed rising trends in prescribing GLP-1RAs, particularly among users with obesity," the authors write. "These findings call for strategies to address the growing demand and ensure equitable access to GLP-1RAs."

Abstract/Full Text (subscription or payment may be required)

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2025 HealthDay. All rights reserved.

Posted July 2024

Read this next

Simultaneous Liver Transplant, Sleeve Gastrectomy Beneficial

FRIDAY, May 9, 2025 -- Simultaneous liver transplant and sleeve gastrectomy (LTSG) yield durable weight loss, resolution of diabetes and hypertension, and a reduction in allograft...

Hyperglycemia, Insulin Resistance in Teens Linked to Worsening Cardiac Damage at Age 24

FRIDAY, May 9, 2025 -- Adolescent hyperglycemia and worsening insulin resistance (IR) are associated with an increased risk for worsening structural and functional cardiac damage...

Metformin Beneficial for Osteoarthritis Knee Pain in Overweight, Obesity

THURSDAY, May 1, 2025 -- For patients with overweight or obesity and symptomatic knee osteoarthritis, metformin is associated with a greater improvement in knee pain than placebo...

More news resources

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.